Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Heart Failure
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Open-label, prospective, randomized, 1:1 intervention arm versus controlMasking: None (Open Label)Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 99 years
- Gender
- Both males and females
Description
This pilot study will be a prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin. All patients will be treated with aspirin 81 mg daily as per the LVAD manufacturer instructions for use (IFU).
This pilot study will be a prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin. All patients will be treated with aspirin 81 mg daily as per the LVAD manufacturer instructions for use (IFU).
Tracking Information
- NCT #
- NCT04865978
- Collaborators
- Abbott Medical Devices
- Investigators
- Principal Investigator: Palak Shah, MD, MS Inova Health System
Get Well Soon